Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, Switzerland. The company operates through two core divisions—Pharmaceuticals and Diagnostics—focusing on the discovery, development and commercialization of innovative medicines and diagnostic tests. In its Pharmaceuticals segment, Roche is a global leader in oncology, immunology, infectious diseases and neuroscience, with a portfolio that includes targeted therapies such as monoclonal antibodies and small-molecule drugs designed to address unmet medical needs.
Founded in 1896 by Fritz Hoffmann-La Roche, the company has grown from a modest vitamin producer into one of the world’s largest biotech firms, with research and production sites spanning Europe, North America and Asia-Pacific. Under the leadership of CEO Thomas Schinecker, who took the helm at the start of 2023, Roche continues to pursue a strategy of personalized healthcare, leveraging advances in biomarkers and companion diagnostics to tailor treatments to individual patients.
Roche Diagnostics is recognized as a pioneer in in vitro diagnostics and tissue diagnostics, offering a broad range of instruments, reagents and software solutions. Its product suite includes molecular diagnostic platforms, immunoassays, clinical chemistry analyzers and point-of-care testing systems. These tools serve hospitals, clinical laboratories and research institutions worldwide, enabling healthcare providers to diagnose diseases earlier and monitor patient responses more effectively.
With a presence in over 100 countries, Roche emphasizes sustained investment in research and development, collaborating with academic institutions, biotech companies and healthcare organizations. The company’s integrated approach to pharmaceuticals and diagnostics underlines its commitment to advancing precision medicine and improving patient outcomes on a global scale.
AI Generated. May Contain Errors.